Skip to main content

Advertisement

SpringerLink
Log in

Oxycodone: a pharmacological and clinical review

  • Review
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Oxycodone is a semi-synthetic opioid with an agonist activity on mu, kappa and delta receptors. Equivalence with regard to morphine is 1:2. Its effect commences one hour after administration and lasts for 12 h in the controlled-release formulation. Plasma half-life is 3–5 h (half that of morphine) and stable plasma levels are reached within 24 h (2–7 days for morphine). Oral bioavailability ranges from 60 to 87%, and plasma protein binding is 45%. Most of the drug is metabolised in the liver, while the rest is excreted by the kidney along with its metabolites. The two main metabolites are oxymorphone — which is also a very potent analgesic — and noroxycodone, a weak analgesic. Oxycodone metabolism is more predictable than that of morphine, and therefore titration is easier. Oxycodone has the same mechanism of action as other opioids: binding to a receptor, inhibition of adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability. These mechanisms also play a part in the onset of dependence and tolerance. The clinical efficacy of oxycodone is similar to that of morphine, with a ratio of 1/1.5–2 for the treatment of cancer pain. Long-term administration may be associated with less toxicity in comparison with morphine. In the future, both opioids could be used simultaneously at low doses to reduce toxicity. It does not appear that there are any differences between immediate and slow-release oxycodone, except their half-life is 3–4 h, and 12 h, respectively. In Spain, controlled-release oxycodone (OxyContin®) is marketed as 10-, 20-, 40-or 80-mg tablets for b.i.d. administration. Tablets must be taken whole and must not be broken, chewed or crushed. There is no food interference. The initial dose is 10 mg b.i.d. for new treatments and no dose reduction is needed in the elderly or in cases of moderate hepatic or renal failure. Immediate-release oxycodone (OxyNorm®) is also available in capsules and oral solution. Side effects are those common to opioids: mainly nausea, constipation and drowsiness. Vomiting, pruritus and dizziness are less common. The intensity of these side effects tends to decrease over the course of time. Oxycodone causes somewhat less nausea, hallucinations and pruritus than morphine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cassinello J (2004) El dolor. Definición, tipos patogénicos, formas de presentación y evaluación del dolor. In Camps C (eds) Manual SEOM de Cuidados Continuos. Dispublic, S.L., Madrid

    Google Scholar 

  2. González Barón M, Ordóñez Gallego A (2003) Dolor y cáncer. Editorial Médica Panamericana, Madrid

    Google Scholar 

  3. González Barón M, Ordóñez Gallego A (2000) Dolor oncológico. Sentido del sufrimiento. In Ortiz JS (ed.) El control del sufrimiento evitable. Terapia analgésica. You and Us, S.A., Madrid

    Google Scholar 

  4. Ordóñez Gallego A, González Barón M (2004) Oxicodona: nuevo opioide. Revista de Oncología 6:203–206

    Google Scholar 

  5. Domínguez G, Gómez Sancho M, Verd M, Brennan LD (2004) Oxicodona, una opción en el manejo del dolor desde 1917. Medicina Paliativa 11:246–263

    Google Scholar 

  6. Ordóñez A, González Barón M, Feliu J et al (2001) Tratamiento de soporte en el enfermo con cáncer. Algunas propuestas basadas en nuestra experiencia. Revista de Oncología 3:266–269

    Google Scholar 

  7. Ordóñez A, De Castro J, Espinosa E et al (2003) Transdermal fentanyl treatment in opioid-naïve cancer patients. Revista de Oncología 5:162–165

    Google Scholar 

  8. Escudero P, Ordóñez A, Cassinello J (2003) Initial doses of fentanyl-TTS based on pain intensity with cancer pain. Thirty-Ninth Annual Meeting ASCO, Chicago, abst. 3123

  9. Poyhia R, Vainio A, Kalso E (1993) A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 8:63–67

    Article  PubMed  CAS  Google Scholar 

  10. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE (1997) Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 121:834–840

    Article  PubMed  CAS  Google Scholar 

  11. Ross FB, Smith MT (1997) The intrinsic antinociceptive effects of oxycodone appear to be k-opioid receptor mediated. Pain 73:151–157

    Article  PubMed  CAS  Google Scholar 

  12. Smith MT, Ross FB, Nielsen CK, Saini K (2001) Oxycodone has a distinctly different pharmacology from morphine. Eur J Pain 5[Suppl A]:135–136

    Article  CAS  Google Scholar 

  13. Varga J, Dickerson ED, Davis MP (2001) United States prescribing habits: what’s going on? (abstract) Support Care Cancer 9:311

    Google Scholar 

  14. Falk E (1917) Eukodal, ein neues narkotikum. Munch Med Wochenschr 20:381–384

    Google Scholar 

  15. Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18:S3–S13

    Article  PubMed  Google Scholar 

  16. Levy MH (2001) Advancement of opioid analgesia with controlled-release oxycodone. Eur J Pain 5[Suppl A]:113–116

    Article  PubMed  CAS  Google Scholar 

  17. Evans PJD (1999) Controlled-release oxycodone: do we need another opiate analgesic? Eur J Pain 3:67–68

    Article  Google Scholar 

  18. Colucci RD, Swanton RE, Gordon ThB, Kaiko RF (2001) Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine. Am J Ther 8:231–236

    Article  PubMed  CAS  Google Scholar 

  19. Benziger DP, Kaiko RF, Miotto JB et al (1996) Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. J Pharm Sci 85:407–410

    Article  PubMed  CAS  Google Scholar 

  20. Davis M, Wilcock A (2001) Modified-release opioids. Eur J Palliat Care 8:142–146

    Google Scholar 

  21. Heiskanen T, Olkkola KT, Kalso E (1998) Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 64:603–611

    Article  PubMed  CAS  Google Scholar 

  22. Leow KP, Cramond T, Smith MT (1995) Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 80:296–302

    Article  PubMed  CAS  Google Scholar 

  23. Kaiko RF, Benzinger DP, Fitzmartin RD et al (1996) Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 59:52–61

    Article  PubMed  CAS  Google Scholar 

  24. Davis MP, Varga J, Dickerson D et al (2003) Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 11:84–92

    PubMed  Google Scholar 

  25. Poyhia R, Seppala T, Oikkola KT, Kalso E (1992) The pharmacokinetics and metabolism of oxycodone alter intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33:617–621

    PubMed  CAS  Google Scholar 

  26. Flórez J, Reig E (1993) Terapéutica farmacológica del dolor. Ediciones Universidad de Navarra S.A., Pamplona

    Google Scholar 

  27. Belda C, Fresno JA, Ceja P, González Barón M (2003) Bases moleculares de la respuesta a los opioides. In Ordóñez Gallego A, González Barón M (eds) Dolor y cáncer. Hacia una oncología sin dolor. Editorial Médica Panamericana S.A., Madrid

    Google Scholar 

  28. Watson PN, Babul N (1998) Efficacy of oxycodone in neuropathic pain a randomized trial in postherpetic neuralgia. Neurology 58:1837–1841

    Google Scholar 

  29. Hale ME, Fleischman R, Salzman R et al (1999) Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 15:179–183

    Article  PubMed  CAS  Google Scholar 

  30. Kampe S, Warm S, Kaufmann J et al (2004) Clinical efficacy of controlled-release oxycodone 20 mg administered on a 12-h dosing schedule on the management of postoperative pain after breast surgery for cancer. Curr Med Res Opin 20:199–202

    Article  PubMed  CAS  Google Scholar 

  31. Hagen N, Babul N (1997) Comparative clinical efficacy and safety of a novel controlled release oxycodone formulation and controlled release hydromorphone in the treatment of cancer pain. Cancer 79:1428–1437

    Article  PubMed  CAS  Google Scholar 

  32. Heiskanen T, Kalso E (1997) Controlled-release oxycodone and morphine in cancer related pain. Pain 73:37–45

    Article  PubMed  CAS  Google Scholar 

  33. Citron M, Kaplan R, Parris W et al (1998) Long-term administration of controlled release oxycodone tablets for the treatment of cancer pain. Cancer Invest 16:562–571

    PubMed  CAS  Google Scholar 

  34. Mucci-LeRusso P, Berman BS, Silberstein PT et al (1998) Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double blind, parallel-group study. Eur J Pain 2:239–249

    Article  Google Scholar 

  35. Bruera E, Belzile M, Pituskin E (1998) Randomized, double blind cross over trial comparing safety and efficacy of oral controlled release oxycodone with controlled release morphine in patients with cancer pain. J Clin Oncol 16:3222–3229

    PubMed  CAS  Google Scholar 

  36. Kaplan R, Parris W, Citron M et al (1998) Comparison of controlled-release and immediate release oxycodone tablets in patients with cancer pain. J Clin Oncol 16:3230–3237

    PubMed  CAS  Google Scholar 

  37. Parris W, Johnson B, Croghan M et al (1998) The use of controlled release oxycodone for the treatment of chronic cancer pain: a randomised, double-blind study. J Pain Symptom Manage 16:205–211

    Article  PubMed  CAS  Google Scholar 

  38. Salzman R, Roberts M, Wild J et al (1999) Can a controlled release oral dose form of oxycodone be used as readily as an immediate release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 18:271–279

    Article  PubMed  CAS  Google Scholar 

  39. Stambaugh JE, Reder RF (2001) Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled-and immediate-release oral oxycodone in cancer pain patients. J Clin Pharmacol 41:500–506

    Article  PubMed  CAS  Google Scholar 

  40. Lauretti GR, Oliveira GM, Pereira NL (2003) Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 89:2027–2030

    Article  PubMed  CAS  Google Scholar 

  41. Ripamonti C, Dickerson D (2001) Strategies for the treatment of cancer pain in the New Millennium. Drugs 61:955–977

    Article  PubMed  CAS  Google Scholar 

  42. Ross FB, Wallis SC, Smith MT (2000) Co-administration of sub-antinociceptive synergy with reduced CSN side-effects in rats. Pain 84:421–428

    Article  PubMed  CAS  Google Scholar 

  43. Riley J, Ross J, Rutter D et al (2006) No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 14:56–64

    Article  PubMed  Google Scholar 

  44. Watson CPN, Moulin D et al (2003) Controlledrelease oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105:71–78

    Article  PubMed  CAS  Google Scholar 

  45. Gimbel J, Richards P, Portenoy RK (2003) Controlled-release oxycodone for pain in diabetic neuropathy. Neurology 60:894–895

    Google Scholar 

  46. Finnerup NB, Otto M, McQuay HJ et al (2005) Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118:289–305

    Article  PubMed  CAS  Google Scholar 

  47. Wallsch TM (2002) Oxycodone retard in a patient suffering form a polyneuropathy with burning dysaesthesia. Neurol Rehabil 8:208–210

    Google Scholar 

  48. Roth SH et al (2000) Around the clock, controlled-release oxycodone therapy for osteoarthritis related pain. Placebo controlled trial and long term evaluation. Arch Intern Med 160:853–860

    Article  PubMed  CAS  Google Scholar 

  49. Ytteberg SR, Mahowald ML, Woods SR (1998) Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum 41:1603–1612

    Article  Google Scholar 

  50. Caldwell JR, Hale ME, Boyd RE et al (1999) Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double-blind, randomized, multicenter, placebo controlled trial. J Rheumatol 26:862–869

    PubMed  CAS  Google Scholar 

  51. McCroskery E, Croft J, Markenson J et al (2000) 3-month efficacy and safety study of OxyContin in osteoarthritis patients. Proceedings of EFIC, Sep 26–29, Nice, France

  52. Markeson JA, Croft J, Zhang PG et al (1996) Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone. Br J Clin Pharmacol 42:747–756

    Article  Google Scholar 

  53. Zautra AJ, Bruce BW (2005) Impact of controlled-release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clin J Pain 21: 471–477

    Article  PubMed  Google Scholar 

  54. Gammaitoni AR et al (2003) Effectiveness and safety of new oxycodone/acetaminophen formulations with reduced acetaminophen for the treatment of low back pain. Pain Med 4: 21–30

    Article  PubMed  Google Scholar 

  55. Überall MA, Mueller-Schwefe G (2005) Untreated pain-optimizing multidisciplinary rehabilitation programs in high-risk patients with chronic low back pain using WHO-III opioid oxycodone. Abstracts, 11th World Congress on Pain

  56. Krämer J (2005) Effective and safe treatment of lumbar root compression syndrome with sustained-release oxycodone. Abstracts, 11th World Congress on Pain

  57. Reuben SS, Connelly NR, Maciolek H (1999) Postoperative analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament surgery. Anesth Analg 88:1286–1291

    Article  PubMed  CAS  Google Scholar 

  58. Cheville A, Chen A, Oster G et al (2001) A randomized trial of controlled-release oxycodone during inpatient rehabilitation following unilateral total knee arthroplasty. J Bone Joint Surg 83A:572–576

    Google Scholar 

  59. Wirz S et al (2005) Post-operative pain therapy with controlled release oxycodone or controlled release tramadol following orthopaedic surgery: a prospective, randomized, double-blind investigation. Pain Clin 17:367–376

    Article  Google Scholar 

  60. de Beer JdeV, Winemaker MJ, Donnelly GA et al (2005) Efficacy and safety of controlled-release oxycodone and standard therapies for postoperative pain after knee or hip replacement. Can J Surg 48: 277–283

    PubMed  Google Scholar 

  61. Hohwü L, Akre O, Bergenwald L et al (2006) Oral oxycodone hydrochloride versus epidural anaesthesia for pain control after radical retropubic prostatectomy. Scand J Urol Nephrol 40:192–197

    Article  PubMed  CAS  Google Scholar 

  62. Staal C, Drenes AM (2004) Experimental human pain models: a review standardised methods for preclinical testing of analgesics. Basic Clin Pharmacol Toxicol 95:97–111

    Google Scholar 

  63. Sorensen TR, Staal C, Arendt-Nielsen L et al (2006) Differential effects of opioids in patients with chronic pancreatitis. An experimental pain study. Digestive Disease Week, Los Angeles, USA, 2006. Poster no. 223486

  64. Staal C, Christrup LL, Andersen SD et al (2006) A comparative study of oxycodone and morphine in a multimodal, tissue differentiated experimental pain model. Pain 123:28–36

    Article  CAS  Google Scholar 

  65. Bezinger D, Kaiko R, Mohito J et al (1996) Differential effects of food on the bioavailability of controlled release oxycodone tablets and immediate release oxycodone solution. J Pharm Sci 58:407–410

    Google Scholar 

  66. Borrás JL, Rodríguez D, Lafuerza A (2004) Manejo del dolor complejo. In Camps C (eds) Manual SEOM de Cuidados Continuos. Dispublic S.L., Madrid

    Google Scholar 

  67. Vilches Y, De Luis V, González Barón M (2003) Rotación de opioides. In González Barón M, Ordóñez Gallego A (eds) Dolor y cáncer. Hacia una oncología sin dolor. Editorial Médica Panamericana S.A., Madrid

    Google Scholar 

  68. Hanks GW, De Conno F, Cherny N et al (2002) Morfina y opiáceos alternativos para el tratamiento del dolor oncológico. Medicina Paliativa 9:22–29

    Google Scholar 

  69. Rischitelli G, Karbowicz SH (2002) Safety and efficacy of controlled-release oxycodone: a systematic literature review. Pharmacotherapy 22:898–904

    Article  PubMed  CAS  Google Scholar 

  70. Maddocks I, Somogyi A, Abbott F et al (1996) Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 12:182–189

    Article  PubMed  CAS  Google Scholar 

  71. Davis M, Tailcock A (2001) Modified-release opioids. Eur J Palliative Care 8:142–146

    Google Scholar 

  72. Ripamonti C, Bruera E (1997) CNS adverse effects of opioids in cancer patients. Guidelines for treatment. CNS Drugs 8:21–37

    CAS  Google Scholar 

  73. Saarialho-Kere U, Mattila MJ, Seppala T (1989) Psychomotor, respiratory and neuroendocrinological effects of a Mu-opioid receptor agonist (oxycodone) in healthy volunteers. Pharmacol Toxicol 65:252–257

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Service. “La Paz” University Hospital Madrid. Cátedra de Oncología y Medicina Paliativa., Universidad Autónoma de Madrid, Madrid, Spain

    A. Ordóñez Gallego, M. González Barón & E. Espinosa Arranz

Authors
  1. A. Ordóñez Gallego
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. González Barón
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Espinosa Arranz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Ordóñez Gallego.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ordóñez Gallego, A., González Barón, M. & Espinosa Arranz, E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol 9, 298–307 (2007). https://doi.org/10.1007/s12094-007-0057-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-007-0057-9

Key words

Search

Navigation